What changed in Madrigal Pharmaceuticals, Inc.'s latest annual report
In the year ended 31 Dec 2025, Madrigal Pharmaceuticals, Inc.'s revenue rose 432.1% to USD 958.40m, from USD 180.13m; long-term debt rose 189.1% to USD 339.88m, from USD 117.57m; total liabilities rose 128.2% to USD 656.90m, from USD 287.86m.
Year ended 31 Dec 2025. Source: 10-K filed 19 Feb 2026, read it on SEC EDGAR.
USD 180.13m to USD 958.40m
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 180.13m | 958.40m | Up 432.1% |
| Net income | -465.89m | -288.28m | Not comparable |
| Total assets | 1.04bn | 1.26bn | Up 20.9% |
| Total liabilities | 287.86m | 656.90m | Up 128.2% |
| Long-term debt | 117.57m | 339.88m | Up 189.1% |
| Cash and cash equivalents | 100.02m | 198.69m | Up 98.7% |
| Shareholders' equity | 754.38m | 602.69m | Down 20.1% |
Questions people ask
Did Madrigal Pharmaceuticals, Inc.'s revenue grow last year?
Revenue grew 432.1%, from USD 180.13m to USD 958.40m in the year ended 31 Dec 2025.
Is Madrigal Pharmaceuticals, Inc. profitable?
Not in its latest year: it reported a net loss of USD 288.28m in the year ended 31 Dec 2025. The year before: a net loss of USD 465.89m.
How much cash and debt does Madrigal Pharmaceuticals, Inc. have?
At its latest year end (31 Dec 2025), Madrigal Pharmaceuticals, Inc. reported cash and cash equivalents of USD 198.69m and long-term debt of USD 339.88m.
Where do these numbers come from?
From Madrigal Pharmaceuticals, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Madrigal Pharmaceuticals, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%